SEC Form 4 · accession 0001179110-17-010735
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric R Olson
Officer — Chief Scientific Officer
Period of report
Jul 25, 2017
Accepted (ET)
Jul 27, 2017 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 25, 2017 | M | 12,500 | $1.01 | A | 12,500 | D | |
| Common Stock | Jul 25, 2017 | S | 12,500 | $21.85 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.01 | Jul 25, 2017 | M | 12,500 | A | — | May 22, 2023 | Common Stock | 12,500 | 25,025 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This option is fully vested.